Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
2.100
+0.100 (5.00%)
At close: Oct 9, 2025, 4:00 PM EDT
2.250
+0.150 (7.14%)
After-hours: Oct 9, 2025, 7:59 PM EDT
Palisade Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
19.15M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 250.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PALI News
- 7 hours ago - Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewsWire
- 7 days ago - Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option - GlobeNewsWire
- 8 days ago - Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - GlobeNewsWire
- 13 days ago - Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum - GlobeNewsWire
- 22 days ago - Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data - GlobeNewsWire
- 4 weeks ago - Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD) - GlobeNewsWire
- 6 weeks ago - Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108 - GlobeNewsWire
- 2 months ago - Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108 - GlobeNewsWire